Business Context and Reporting Period
This Form 8-K Current Report was filed by Curis, Inc. on September 19, 2006, covering events occurring on September 13 and September 14, 2006. The filing discloses the entry into two material definitive agreements involving key scientific personnel.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on contractual obligations and equity compensation.
- Consulting Fee Cap (Rubin): Maximum aggregate payment of $40,000 over a three-year term.
- Consulting Rate (Rubin): $1,200 per day or $150 per hour.
- Annual Retainer (Davie): $25,000 per year, effective upon termination of a prior agreement.
- Stock Option Grant (Rubin): 250,000 shares at an exercise price of $1.57.
- Stock Option Grant (Davie): 35,000 shares at an exercise price of $1.72.
Material Changes and Agreements
Consulting Agreement with Lee Rubin, Ph.D.
Effective September 13, 2006, the Company entered into a three-year agreement with former Chief Scientific Officer Lee Rubin. Dr. Rubin will provide consulting services on Hedgehog and Wnt programs, including drug development and lead candidate evaluation. The agreement is terminable by either party with 30 days' written notice.
Scientific Advisory Agreement with Joseph M. Davie, Ph.D., M.D.
Effective September 14, 2006, the Company entered into a five-year agreement with Board member and Interim Chief Scientific Officer Joseph M. Davie. Dr. Davie will serve as Chairman of the Scientific Advisory Board, providing services in developmental biology, oncology, and neurobiology. The $25,000 annual retainer is contingent on the termination of his prior consulting agreement dated June 19, 2006.
Guidance, Risks, and Contingencies
The filing does not contain financial guidance or general risk factors. Specific contingencies include:
- Performance Milestones: Dr. Rubin's stock options are exercisable only upon the achievement of specified performance milestones by the Company.
- Service Contingency: Both agreements are contingent upon the continued service of the respective individuals. Dr. Davie's options vest quarterly (6.25% every three months) contingent on continued service.
- Termination Rights: Both agreements allow for termination with 30 days' written notice by either party.
Investor Verification Checklist
- Verify the specific performance milestones required for Dr. Rubin's 250,000 stock options to become exercisable.
- Confirm the status and termination date of Dr. Davie's prior consulting agreement (dated June 19, 2006) to determine when the $25,000 annual retainer becomes effective.
- Review the full text of Exhibits 10.1 and 10.2 for detailed scope of work and additional compensation terms.
- Assess the impact of these agreements on the Company's cash burn rate relative to its current liquidity position (not provided in this filing).